

## SUPPLEMENTAL MATERIAL

### **A Genome Wide Association Study for Coronary Artery Disease Identifies a Novel Susceptibility Locus in the Major Histocompatibility Complex**

#### **Index**

Supplementary Methods .....	2
Supplemental Table 1. Stage 1 Studies SNP Details .....	4
Supplemental Table 2. Loci Which Met Discovery Threshold .....	5
Supplemental Table 3. Replication and Global Meta-Analysis of Putative Loci .....	6
Supplemental Figure 1. First two principal components from discovery cohorts .....	8
Supplemental Figure 2. First two principal components from merged discovery cohorts .....	9

## Supplementary Methods

### Cohort descriptions

***OHGS\_A and OHGS\_CCGB\_B:*** Details on study criteria for the Ottawa Heart Genomics Study (OHGS), in collaboration with the Cleveland Clinic GeneBank (CCGB), have been published previously.<sup>1</sup> For the purposes of this study, subjects were divided into two cohorts; those genotyped on the Affymetrix 500K (OHGS\_A) and those on the Affymetrix 6.0 (OHGS\_CCGB\_B). Note that these are different from previously published studies, such as CARDIoGRAM<sup>2</sup>, which featured OHGS1 and OHGS2; the re-branding into OHGS\_A and OHGS\_B was primarily done to ensure uniformity of array type in OHGS\_A and OHGS\_B, as OHGS1 was a mix of Affymetrix 500K and 6.0 arrays.

Cases and controls were recruited from each of the lipid clinic at the University of Ottawa Heart Institute (UOHI), the catheterization laboratory at the UOHI, or at the catheterization laboratory of the Cleveland Clinic (CC). All cases in OHGS\_A and OHGS\_CCGB\_B were required to have at least one of: a stenosis in a major epicardial vessel of at least 50%; have had a percutaneous intervention (PCI); have had coronary artery bypass surgery (CABG); or have had a myocardial infarction (MI). Cases with diabetes mellitus were excluded. Age of onset of CAD was required to be  $\leq 55$ y for men and  $\leq 65$ y for women. Controls were either healthy asymptomatic elderly individuals (UOHI) or were recruited through the catheterization laboratory at either the UOHI or the CC with no stenosis  $\geq 50\%$  in any major epicardial vessel and were required to be  $\geq$  at least 65y for men and  $\geq 70$ y for women. The study protocol was approved by the Human Research Ethics Board of the University of Ottawa Heart Institute and all participants provided informed consent.

***DUKE:*** Details on the study criteria for the Duke Cathgen study (DUKE) as used in this study have not been published previously. Subjects were recruited from the catheterization laboratory at Duke. Cases had at least one epicardial coronary vessel with  $\geq 50\%$  stenosis. Cases were required to be  $\leq 55$ y for men and  $\leq 65$ y for women. Controls were required to be  $\geq 50$  y. Any subject with diabetes mellitus, severe pulmonary hypertension or congenital heart disease was excluded. Controls were required to have no epicardial coronary vessel with  $\geq 30\%$  stenosis. Controls with a history of ICC/PCI, CABG, MI or transplant were excluded. The study protocol was approved by the ethics committee and all participants provided informed consent.

***ITH:*** Details of the INTERHEART cohort have been published previously.<sup>3</sup> Briefly, INTERHEART is a standardized case-control study of acute MI from 262 centers in 52 countries. Women and men were recruited in Asia, Europe, the Middle East, Africa, Australia, North America, and South America. Only self-described Caucasian participants were considered for the present analysis. Briefly, cases of incident acute MI, presenting to a hospital within 24 hours of symptom onset, were age- ( $\pm 5$  y) and sex-matched with controls who were hospital- or community-based individuals with no previous diagnosis of heart disease or history of

exertional chest pain. A subset of the INTERHEART cohort (<1000) of self-described European ancestry was available for analysis in the present study. The study protocol was approved by the ethics committees in all participating centers and all participants provided informed consent. A full list of ITH investigators is found at <http://www.phri.ca/interheart/index2.html>.

**WTCCC:** Details of the Wellcome Trust Case Control Consortium (WTCCC) CAD cohort have been published previously.<sup>4</sup> Briefly, cases had a history of MI, CABG or PCI. Cases were required to be  $\leq 65$ y. Controls subjects were recruited from the National Blood Services and the 1958 Birth Cohort with no specific age or phenotype exclusions.

### **Description of Stage 2 Studies**

**GerMIFS and GerMIFS2:** Details of the German Myocardial Infarction Family Study (GerMIFS1 and GerMIFS2) have been published previously.<sup>5, 6</sup> Cases in GerMIFS1 had a history of MI and were required to have at least one first degree relative with premature coronary artery disease. Cases in GerMIFS2 also had a history of MI and most had a family history of disease (59.4%). Cases were required to be  $\leq 60$ y. Controls for both GerMIFS1 and GerMIFS2 were population controls. The study protocol was approved by the ethics committees in all participating centers and all participants provided informed consent.

**PennCath/MedStar:** Details of the PennCath and MedStar cohorts have been published previously.<sup>7</sup> Briefly, cases and controls were recruited from the catheterization laboratory at the University of Pennsylvania Medical Center (PennCath) and the catheterization laboratory at the Washington Hospital Center by the MedStar Health Research Institute (MedStar). Cases were required to have at least one stenosis of  $\geq 50\%$  in at least one major epicardial vessel; controls were required to have no stenoses exceeding 10% in any vessel. Cases were required to be  $\leq 55$ y for men and  $\leq 65$ y for women; controls were required to be aged at least 45 (40 for men in PennCath). The study protocol was approved by the ethics committees in all participating centers and all participants provided informed consent.

**OHGS\_CCGB\_S:** The Ottawa Heart Genomics Consortium in collaboration with the Cleveland Clinic GeneBank Supplementary (OHGS\_CCGB\_S) cohort has not been published previously. OHGS\_CCGB\_S is a supplementary cohort assembled for the purposes of this study. Cases are derived both the UOHI and CC and were genotyped following the primary meta-analysis. Cases were required to be  $\leq 65$ y for men and  $\leq 70$ y for women. Cases with diabetes mellitus were removed. Controls for OHGS\_CCGB\_S came from the WTCCC2; specifically, we used more recently recruited controls distinct from those used in the original WTCCC publication.<sup>6</sup>

## Supplemental Table 1. Stage 1 Studies SNP Details

Type	Model	Value	OHGS_A	OHGS_ CCGB_B	DUKE	WTCCC	ITH	Meta- analysis
G	add	N	367,036	640,404	499,931	399,471	648,636	N/A
G	add	$\lambda$	1.112	1.126	1.024	1.070	1.018	N/A
G	dom	N	359,551	631,530	476,439	388,193	620,261	N/A
G	dom	$\lambda$	1.060	1.095	0.961	1.029	0.958	N/A
G	rec	N	358,525	631,163	480,726	387,575	618,582	N/A
G	rec	$\lambda$	1.051	1.094	0.970	1.032	0.956	N/A
I	add	N	4,389,233	5,501,436	4,102,281	4,582,413	5,441,076	4,916,498
I	add	$\lambda$	1.094	1.107	1.014	1.059	1.007	1.032
I	dom	N	4,340,557	5,463,566	4,034,131	4,543,802	5,354,571	4,889,746
I	dom	$\lambda$	1.073	1.088	1.001	1.032	0.991	1.036
I	rec	N	3,930,417	5,163,210	3,543,352	4,268,249	4,606,865	4,637,828
I	rec	$\lambda$	0.927	0.977	0.850	0.933	0.832	0.918

G = Genotyped, I = Imputed, add=Additive, dom=Dominant, rec=Recessive  
 Note that the number of dominant or recessive SNPs may be lower than additive due to instances where the relevant homozygote is not present. Also note the difference between recessive and dominant lambdas post-imputation; this is largely driven by fact that the major allele distribution is highly non-symmetric in the haplotypic imputation panel as opposed to the original genotyped data.

## Supplemental Table 2. Loci Which Met Discovery Threshold

rsid	Rank	Gene or band	Ref <sup>1</sup>	p add	p dom	p rec	best	MOI	MOI p-value
rs1333049	1	9p21.3	4, 6, 8, 9	2.91E-32	2.07E-24	2.93E-21	2.91E-32	add	2.91E-32
rs11556924	2	ZC3HC1	10	2.81E-08	4.33E-06	2.07E-06	2.81E-08	add	2.81E-08
rs629301	3	SORT1	6	1.19E-07	0.000915	4.82E-07	1.19E-07	add	1.19E-07
rs12006148	4	4p15.3		1.97E-05	1.81E-07	0.236911	1.81E-07	dom	1.81E-07
rs3740107	5	ALOX5		7.92E-06	0.506477	1.85E-07	1.85E-07	rec	1.85E-07
rs2133189	6	MIA3	11	2.73E-07	1.96E-05	1.36E-05	2.73E-07	add	2.73E-07
rs9295125	7	LPA	12, 13	4.64E-07	3.19E-07	0.002957	3.19E-07	dom	3.19E-07
rs3869109	8	HCG27/HLA-C		3.30E-07	1.23E-05	3.45E-05	3.30E-07	add	3.3E-07
rs7278845	9	MRPS6/KCNE2	11	3.76E-07	3.61E-07	0.036935	3.61E-07	dom	3.61E-07
rs73196173	10	DIAPH3		4.22E-07	4.79E-07	0.111914	4.22E-07	dom	4.79E-07
rs2301241	11	TXN		1.30E-05	5.19E-07	0.016414	5.19E-07	dom	5.19E-07
rs6982502	12	TRIB1	14	5.35E-07	5.14E-05	1.77E-05	5.35E-07	add	5.35E-07
rs73013202	13	LDLR	11	8.73E-07	7.15E-07	0.014376	7.15E-07	dom	7.15E-07
rs12503914	14	GALNT7		2.49E-05	8.86E-07	0.268191	8.86E-07	dom	8.86E-07
rs2247374	15	FAM129B		0.496035	1.10E-06	0.289277	1.10E-06	dom	1.1E-06
rs12651275	16	4q31.3		0.112958	0.974024	1.14E-06	1.14E-06	rec	1.14E-06
rs2229238	17	ILR6		0.003164	1.25E-06	0.123347	1.25E-06	dom	1.25E-06
rs952227	18	2q26 / rs952227 <sup>2</sup>		1.05E-06	0.003116	1.57E-06	1.05E-06	rec	1.57E-06
rs35008336	19	PKDIL2		4.08E-06	1.80E-06	0.027632	1.80E-06	dom	1.8E-06
rs4675310	20	WDR12	11	4.60E-06	0.142034	1.85E-06	1.85E-06	rec	1.85E-06
8-9862032	21	8p23.1		7.73E-06	2.40E-06	0.871994	2.40E-06	dom	2.4E-06
rs9625066	22	MIAT		0.000208	0.023167	2.56E-06	2.56E-06	rec	2.56E-06
rs1919484	23	LPL	14	2.68E-06	0.000175	1.31E-05	2.68E-06	add	2.68E-06
rs1537340	24	PHACTR1	11	4.73E-05	2.77E-06	0.288574	2.77E-06	dom	2.77E-06
rs10779058	25	12q21.3		9.39E-05	3.22E-06	0.084287	3.22E-06	dom	3.22E-06
rs501120	26	CXCL12	6, 11	9.58E-07	3.70E-06	0.004097	9.58E-07	dom	3.7E-06
4-130146736	27	SCLT1		0.00796	0.280579	3.73E-06	3.73E-06	rec	3.73E-06
rs6905288	28	VEGFA		0.000314	3.98E-06	0.091886	3.98E-06	dom	3.98E-06
rs17114046	29	PPAP2B	10	8.73E-06	4.04E-06	0.250999	4.04E-06	dom	4.04E-06
rs12200560	30	FHL5		4.09E-06	0.000173	9.14E-05	4.09E-06	add	4.09E-06
rs9894220	31	UBE2Z	10	2.77E-05	4.10E-06	0.034446	4.10E-06	dom	4.1E-06
rs6001811	32	TNRC6B		5.59E-05	4.15E-06	0.10883	4.15E-06	dom	4.15E-06
9-135134129	33	ABO	7, 10	1.91E-05	4.20E-06	0.097983	4.20E-06	dom	4.2E-06
rs6958243	34	CASD1		0.000382	0.243518	4.39E-06	4.39E-06	rec	4.39E-06
rs73241008	35	13q31.1		0.167896	0.845427	4.42E-06	4.42E-06	rec	4.42E-06
rs10182781	36	2p25.1		0.000226	0.825524	4.66E-06	4.66E-06	rec	4.66E-06
rs17458018	37	FN		1.17E-05	4.92E-06	0.514205	4.92E-06	dom	4.92E-06

MOI = Method of Inheritance, add=Additive, dom=Dominant, rec=Recessive, ref=Reference

<sup>1</sup> Reference refers to the original publication (values correspond to main text reference list)

<sup>2</sup> rs952227 was suggested to be associated with CAD based on the original WTCCC publication, but this association has not been convincingly replicated, and in this analysis the association was largely driven by the WTCCC cohort.

### Supplemental Table 3. Replication and Global Meta-Analysis of Putative Loci

rsID	Locus	MOI	AL	AF <sup>1</sup>	CAF <sup>2</sup>	Discovery				Replication				Global			
						OR	p	N	I <sup>2</sup>	OR	P	N	I <sup>2</sup>	OR	P	N	I <sup>2</sup>
rs12006148	4p15.3	dom	G	35.8	58.1	1.24	1.81E-07	4	0.0	1.01	8.80E-01	5	0.0	1.13	8.56E-05	9	50.2
rs3740107	ALOX5	rec	G	72.1	50.0	1.23	1.85E-07	4	17.8	0.94	1.90E-01	3	0.0	1.11	1.09E-03	7	73.4
rs3869109	HCG27/HLA-C	add	G	54.5	54.5	1.16	3.3E-07	4	0.0	1.11	5.28E-04	5	0.0	1.14	1.12E-09	9	0.0
rs2301241	TXN	dom	A	59.4	84.5	0.67	5.19E-07	2	0.0	1.04	6.36E-01	2	0.0	0.83	9.59E-04	4	80.9
rs73196173	DIAPH3	dom	C	6.2	11.9	0.74	5.94E-07	5	11.8	1.08	2.87E-01	5	21.1	0.87	2.05E-03	10	65.6
rs12503914	GALNT7	dom	T	32.1	55.7	0.82	8.86E-07	4	0.0	0.98	7.13E-01	3	0.0	0.88	5.16E-05	7	47.0
rs2247374	FAM129B	dom	T	82.4	97.6	0.57	1.1E-06	4	0.0	1.12	3.79E-01	5	0.0	0.76	1.86E-03	9	58.3
rs12651275	4q31.3	rec	T	15.4	4.2	0.39	1.14E-06	2	0.0	0.89	5.26E-01	4	49.2	0.60	1.23E-04	6	67.6
rs2229238	ILR6	dom	C	82.1	97.0	0.61	1.25E-06	5	12.0	0.79	4.34E-02	4	65.0	0.69	6.91E-07	9	50.2
rs35008336	PKDIL2	dom	T	29.7	50.6	0.81	1.8E-06	3	0.0	1.00	9.91E-01	5	43.1	0.90	8.14E-04	8	65.1
8-9862032	8p23.1	dom	C	1.3	2.6	1.63	2.4E-06	5	0.0	0.94	7.11E-01	3	42.3	1.40	1.42E-04	8	43.6
rs9625066	MIAT	rec	A	30.0	10.1	0.57	2.56E-06	2	0.0	1.02	8.53E-01	3	0.0	0.77	1.82E-03	5	72.3
rs10779058	12q21.3	dom	A	46.4	69.6	1.21	3.22E-06	5	39.4	1.04	5.20E-01	3	0.0	1.15	3.57E-05	8	42.2
4-130146736	SCLT1	rec	G	22.5	3.7	1.98	3.73E-06	2	0.0	0.79	8.17E-02	2	71.7	1.20	6.33E-02	4	87.8
rs6905288	VEGFA	dom	T	55.9	79.4	1.28	3.98E-06	3	0.0	1.18	2.97E-03	5	77.2	1.23	6.97E-08	8	62.7
rs12200560	FHL5	add	A	50.8	50.8	0.88	4.1E-06	5	0.0	0.92	2.94E-02	3	0.0	0.90	5.99E-07	8	0.0
rs6001811	TNRC6B	dom	G	34.5	55.6	1.34	4.15E-06	2	0.0	1.08	1.52E-01	3	0.0	1.18	5.23E-05	5	46.3
rs6958243	CASD1	rec	C	56.2	32.4	0.80	4.39E-06	3	26.9	1.02	6.96E-01	3	0.0	0.89	1.41E-03	6	65.2
rs73241008	13q31.1	rec	C	19.2	2.6	1.60	4.42E-06	5	0.0	1.11	3.15E-01	5	0.0	1.34	7.39E-05	10	20.0
rs10182781	2p25.1	rec	C	69.9	46.7	1.33	4.66E-06	2	0.0	0.92	1.03E-01	3	80.6	1.07	1.02E-01	5	87.2
rs17458018	FN	dom	C	6.5	12.7	0.77	4.92E-06	5	0.0	0.90	1.16E-01	5	0.0	0.82	6.90E-06	10	0.0

MOI = Method of Inheritance, AL = Allele, AF = Allele Frequency, CAF = Current Allele Frequency


<sup>1</sup> Allele Frequency refers to the traditional (minor) allele frequency

<sup>2</sup> Current allele Frequency refers to the frequency of the risk variant. For an additive SNP, this is the traditional minor allele frequency. For a dominant SNP, having two copies of the allele represents the risk variant, so CAF is the frequency of people who are heterozygote and homozygote AL/AL. For a recessive SNP, CAF is the frequency of being homozygote for AL/AL.

## Supplemental Table 4. HLA Imputation Accuracy Measures

HLA allele	Proportion below threshold <sup>1</sup>	Allele freq <sup>2</sup>	Median posterior probability
HLA-A*0101	0.019953	0.171444	0.992701
HLA-A*0201	0.018948	0.274935	0.989347
HLA-A*0301	0.004907	0.143075	0.993223
HLA-A*1101	0.006861	0.064501	1
HLA-A*2402	0.039837	0.07876	0.98082
HLA-A*2902	0.011324	0.042146	1
HLA-A*3101	0.016645	0.028518	1
HLA-A*3201	0.040309	0.041552	0.999988
HLA-A*6801	0.064228	0.038953	0.996485
HLA-B*0702	0.01136	0.132797	0.993318
HLA-B*0801	0.01194	0.123195	0.99991
HLA-B*1302	0.01129	0.022815	0.998027
HLA-B*1402	0.018692	0.027356	0.999304
HLA-B*1501	0.021612	0.062342	0.999544
HLA-B*1801	0.024535	0.042914	0.999996
HLA-B*2705	0.01141	0.045147	0.99765
HLA-B*3501	0.052774	0.052107	0.989926
HLA-B*4001	0.00848	0.056573	0.999988
HLA-B*4402	0.015466	0.10425	0.996899
HLA-B*5101	0.031898	0.045184	0.999937
HLA-B*5701	0.036087	0.037777	0.997935
HLA-C*0102	0.035614	0.037763	0.999974
HLA-C*0202	0.017974	0.044112	0.999934
HLA-C*0303	0.038579	0.057617	0.986484
HLA-C*0304	0.029218	0.075599	0.985524
HLA-C*0401	0.005484	0.09982	0.99811
HLA-C*0501	0.010443	0.100848	0.985129
HLA-C*0602	0.015093	0.093398	0.999982
HLA-C*0701	0.027226	0.159969	0.973167
HLA-C*0702	0.006208	0.140996	0.987051
HLA-C*0802	0.067708	0.039414	0.990639
HLA-C*1203	0.023296	0.041543	0.999498
HLA-C*1601	0.011255	0.04191	0.996597
<sup>1</sup> For a specific allele, gives proportion of observed probabilities below threshold of 0.7			
<sup>2</sup> Estimated allele frequency. Does not sum to 1 as low frequency alleles not considered here			


## Supplemental Figure 1. First two principal components from discovery cohorts



Included HapMap phase 2 samples are shown in green (CEU), blue (JPT+CHB) and purple (YRI). Note that the two subjects which would have been removed from this analysis for the WTCCC were retained to facilitate comparisons with the original publication.



## Supplemental Figure 2. First two principal components from merged discovery cohorts



Plot of the first two main principal components in the combined discovery dataset (n=13,949). Superimposed are ethnicities available from a subset of the cohort. Only SNPs common to the Affymetrix 500k, 6.0 and Axiom were considered, which, following QC, 55,032 SNPs (no LD filter was applied). Note that no SNPs from the MHC were included in this analysis (chromosome 6 26-34MBp, build 36).

## Reference List

- (1) Davies RW, Dandona S, Stewart AF, Chen L, Ellis SG, Tang WH, Hazen SL, Roberts R, McPherson R, Wells GA. Improved Prediction of Cardiovascular Disease Based on a Panel of SNPs Identified Through Genome Wide Association Studies. *Circ Cardiovasc Genet*. 2010;3:468-74.
- (2) Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissono D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de FU, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Muhleisen TW, Muhlestein JB, Munzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nothen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schafer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoop JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Wittman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, Marz W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O'Donnell CJ, McPherson R, Erdmann J, Samani NJ. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet*. 2011;43:333-38.
- (3) Anand SS, Xie C, Pare G, Montpetit A, Rangarajan S, McQueen MJ, Cordell HJ, Keavney B, Yusuf S, Hudson TJ, Engert JC. Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: The INTERHEART Genetics Study. *Circ Cardiovasc Genet*. 2009;2:16-25.
- (4) Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*. 2007;447:661-78.
- (5) Erdmann J, Grosshennig A, Braund PS, König IR, Hengstenberg C, Hall AS, Linsel-Nitschke P, Kathiresan S, Wright B, Tregouet DA, Cambien F, Bruse P, Aherrahrou Z, Wagner AK, Stark K, Schwartz SM, Salomaa V, Elosua R, Melander O, Voight BF, O'Donnell CJ, Peltonen L, Siscovick DS, Altshuler D, Merlini PA, Peyvandi F, Bernardinelli L, Ardissono D, Schillert A, Blankenberg S, Zeller T, Wild P, Schwarz DF, Tiret L, Perret C, Schreiber S, El Mokhtari NE, Schafer A, Marz W, Renner W, Bugert P, Kluter H, Schrezenmeir J, Rubin D, Ball SG, Balmforth AJ, Wichmann HE, Meitinger T, Fischer M, Meisinger C, Baumert J, Peters A, Ouwehand WH, Deloukas P, Thompson JR, Ziegler A, Samani NJ, Schunkert H. New susceptibility locus for coronary artery disease on chromosome 3q22.3. *Nat Genet*. 2009;41:280-2.

- (6) Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, König IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson JR, Schunkert H. Genomewide association analysis of coronary artery disease. *N Engl J Med*. 2007;357:443-53.
- (7) Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS, Martinelli N, Girelli D, Quyyumi AA, Anderson JL, Erdmann J, Hall AS, Schunkert H, Quertermous T, Blankenberg S, Hazen SL, Roberts R, Kathiresan S, Samani NJ, Epstein SE, Rader DJ. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. *Lancet*. 2011;377:383-92.
- (8) Helgadóttir A, Thorleifsson G, Manolescu A, Gretarsdóttir S, Blondal T, Jonasdóttir A, Jonasdóttir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM, Matthíasdóttir S, Jónsdóttir T, Palsson S, Einarsson H, Gunnarsdóttir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdóttir U, Kong A, Stefansson K. A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science*. 2007;316:1491-3.
- (9) McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC. A common allele on chromosome 9 associated with coronary heart disease. *Science*. 2007;316:1488-91.
- (10) Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalić M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buyschaert I, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de FU, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdóttir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Muhleisen TW, Muhlestein JB, Munzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nothen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schafer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoop JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Wittman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, Marz W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdóttir U, O'Donnell CJ, McPherson R, Erdmann J, Samani NJ. Large-scale

association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet.* 2011;43:333-8.

- (11) Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H, Erdmann J, Reilly MP, Rader DJ, Morgan T, Spertus JA, Stoll M, Girelli D, McKeown PP, Patterson CC, Siscovick DS, O'Donnell CJ, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Melander O, Altshuler D, Ardissino D, Merlini PA, Berzuini C, Bernardinelli L, Peyvandi F, Tubaro M, Celli P, Ferrario M, Fetiveau R, Marziliano N, Casari G, Galli M, Ribichini F, Rossi M, Bernardi F, Zoncin P, Piazza A, Mannucci PM, Schwartz SM, Siscovick DS, Yee J, Friedlander Y, Elosua R, Marrugat J, Lucas G, Subirana I, Sala J, Ramos R, Kathiresan S, Meigs JB, Williams G, Nathan DM, MacRae CA, O'Donnell CJ, Salomaa V, Havulinna AS, Peltonen L, Melander O, Berglund G, Voight BF, Kathiresan S, Hirschhorn JN, Asselta R, Duga S, Spreafico M, Musunuru K, Daly MJ, Purcell S, Voight BF, Purcell S, Nemes J, Korn JM, McCarroll SA, Schwartz SM, Yee J, Kathiresan S, Lucas G, Subirana I, Elosua R, Surti A, Guiducci C, Gianniny L, Mirel D, Parkin M, Burt N, Gabriel SB, Samani NJ, Thompson JR, Braund PS, Wright BJ, Balmforth AJ, Ball SG, Hall AS, Schunkert H, Erdmann J, Linsel-Nitschke P, Lieb W, Ziegler A, Konig I, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Schunkert H, Samani NJ, Erdmann J, Ouwehand W, Hengstenberg C, Deloukas P, Scholz M, Cambien F, Reilly MP, Li M, Chen Z, Wilensky R, Matthai W, Qasim A, Hakonarson HH, Devaney J, Burnett MS, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Epstein SE, Rader DJ, Scheffold T, Berger K, Stoll M, Huge A, Girelli D, Martinelli N, Olivieri O, Corrocher R, Morgan T, Spertus JA, McKeown P, Patterson CC, Schunkert H, Erdmann E, Linsel-Nitschke P, Lieb W, Ziegler A, Konig IR, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Holm H, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Engert JC, Do R, Xie C, Anand S, Kathiresan S, Ardissino D, Mannucci PM, Siscovick D, O'Donnell CJ, Samani NJ, Melander O, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Altshuler D. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet.* 2009;41:334-41.
- (12) Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de FU, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med.* 2009;361:2518-28.
- (13) Tregouet DA, Konig IR, Erdmann J, Munteanu A, Braund PS, Hall AS, Grosshennig A, Linsel-Nitschke P, Perret C, Desuremain M, Meitinger T, Wright BJ, Preuss M, Balmforth AJ, Ball SG, Meisinger C, Germain C, Evans A, Arveiler D, Luc G, Ruidavets JB, Morrison C, van der HP, Schreiber S, Neureuther K, Schafer A, Bugert P, El Mokhtari NE, Schrezenmeir J, Stark K, Rubin D, Wichmann HE, Hengstenberg C, Ouwehand W, Ziegler A, Tiret L, Thompson JR, Cambien F, Schunkert H, Samani NJ. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. *Nat Genet.* 2009;41:283-5.
- (14) Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin CY, Jin GM, Jin KY, Lee JY, Park T, Kim K, Sim X, Twee-Hee OR, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua ZJ, Yuan X, Luan J, Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Witteman JC, Wilson JF, Willemsen G, Wichmann HE,

Whitfield JB, Waterworth DM, Wareham NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruukonen A, Rudan I, Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BW, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O'Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, Magnusson PK, Lucas G, Luben R, Loos RJ, Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, König IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR, Cecile JWJ, Ingelsson E, Igl W, Kees HG, Hottenga JJ, Hofman A, Hicks AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, Gyllenstein U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Doring A, Dominiczak AF, Demissie S, Deloukas P, de Geus EJ, de FU, Crawford G, Collins FS, Chen YD, Caulfield MJ, Campbell H, Burt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM, Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T, Altshuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS, Taylor HA, Jr., Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U, Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, Kastelein JJ, Schadt EE, Rotter JI, Boerwinkle E, Strachan DP, Mooser V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS, Ridker PM, Rader DJ, van Duijn CM, Peltonen L, Abecasis GR, Boehnke M, Kathiresan S. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*. 2010;466:707-13.